Skip to main content

News & Events Overview


Foundation Medicine Lab Employees pipetting in a lab

An End-to-end Approach to Precision Medicine

FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. Learn more about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.

Read More on Our Blog

From the Foundation Forward Blog

View All Blog Posts

Latest Press Releases

View All Press Releases

Media Contact

Public Relations Team